US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer ...

"Arcus and AstraZeneca enter trial collaboration for renal cancer treatment" was originally created and published by Clinical ...

Wednesday announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan in combination with volrustomig for the treatment of clear cell renal cell carcinoma or ccRCC ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on RCUS stock, giving a Buy rating on September 16. Daina ...

Arcus Biosciences develops late-stage immunotherapies, with Domvanalimab and Casdatifan leading the way. See why I rate RCUS ...

As millions celebrate Labor Day, unions across Minnesota have seen some gains, with several groups recently settling contract talks which included pay increases and better benefits. Hamline ...

While Democratic nominee and Vice President Kamala Harris and Republican nominee and former President Donald Trump enter the home stretch of the presidential campaign, the outcome may very well be ...

The additional capital strengthens Arcus’s balance sheet and increases flexibility to rapidly advance casdatifan, its potential best-in-class HIF-2a inhibitor. Arcus plans to present data from ARC-20, ...

This capital infusion is intended to enhance the company's financial position and advance the development of its cancer treatment candidate, casdatifan. The loan agreement provides Arcus immediate ...

Arcus Biosciences Inc. recently disclosed the chemical structure of AB-521 (casdatifan), an orally available small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α) in early clinical ...